|
n (%)
|
---|
Benguela
|
Zaire
|
Lunda Sul
|
---|
ASAQa
|
ALa
|
ALa
|
DPb
|
DPb
|
ASAQa
|
---|
n = 73
|
n = 85
|
n = 93
|
n = 84
|
n = 76
|
n = 56
|
---|
Treatment failure
|
7 (10)
|
9 (11)
|
23 (25)
|
15 (18)
|
0
|
0
|
Early treatment failure
|
0
|
1 (1)
|
3 (3)
|
0
|
0
|
0
|
Late treatment failure
|
7 (10)
|
8 (9)
|
20 (22)
|
15 (18)
|
0
|
0
|
Recrudescence
|
0
|
1 (1)
|
8 (9)
|
1 (1)
|
0
|
0
|
Day 7
|
0
|
0
|
0
|
0
|
0
|
0
|
Day 14
|
0
|
0
|
2 (2)
|
0
|
0
|
0
|
Day 21
|
0
|
0
|
6 (6)
|
0
|
0
|
0
|
Day 28
|
0
|
1 (1)
|
0
|
1 (1)
|
0
|
0
|
Day 35
|
–
|
–
|
–
|
0
|
0
|
–
|
Day 42
|
–
|
–
|
–
|
0
|
0
|
–
|
Reinfection
|
7 (10)
|
7 (8)
|
12 (13)
|
14 (17)
|
0
|
0
|
Day 7
|
0
|
0
|
0
|
0
|
0
|
0
|
Day 14
|
0
|
2 (2)
|
1 (1)
|
0
|
0
|
0
|
Day 21
|
1 (1)
|
1 (1)
|
6 (6)
|
0
|
0
|
0
|
Day 28
|
6 (8)
|
1 (1)
|
5 (5)
|
3 (4)
|
0
|
0
|
Day 35
|
–
|
–
|
–
|
5 (6)
|
0
|
–
|
Day 42
|
–
|
–
|
–
|
6 (7)
|
0
|
–
|
Adequate clinical and parasitological response
|
66 (90)
|
76 (89)
|
70 (75)
|
69 (82)
|
76 (100)
|
56 (100)
|
-
ASAQ artesunate–amodiaquine, AL artemether–lumefantrine, DP dihydroartemisinin–piperaquine
-
a28-day follow-up
-
b42-day follow-up